Navigation Links
Future hope for patients with breast cancers resistant to tamoxifen
Date:6/16/2008

Researchers have found a new family of therapeutic agents that interferes with the ability of estrogen to stimulate the growth of breast cancer cells. The results of the new study will be presented by Nicole Patterson at The Endocrine Society's 90th Annual Meeting in San Francisco.

The cell-based study suggests that a small-molecule therapeutic called TPBM and related compounds are likely to be effective against breast cancers that depend on estrogen to grow (called estrogen receptor-positive) but that are resistant to current therapies, team leader David Shapiro, PhD, said.

Shapiro, a biochemist at the University of Illinois at Urbana-Champaign, said at detection, about two-thirds of breast cancers are estrogen receptor-positive, and virtually all of these cancers become resistant over time to the breast cancer drug tamoxifen. In some tamoxifen-resistant tumors, tamoxifen begins to act like estrogen and can actually stimulate tumor growth, he explained.

Therefore, researchers are trying to find new ways to block resistance to drugs such as tamoxifen. Shapiro's team developed a technique to screen for chemical compounds that would inhibit the ability of estrogen and the estrogen receptor protein to bind to DNA and turn on gene expression in breast cancer cells.

"We targeted a different step in the pathway of estrogen action, one that is not targeted by current therapeutics," Shapiro said.

They then tested various agents in estrogen receptor-positive breast cancer cells in the laboratory. The team identified a family of compounds related to TPBM that Shapiro said inhibited the estrogen-dependent growth of breast cancer cells.

"TPBM is highly targeted and has little or no toxic effect on other cellsthose that don't depend on the estrogen receptor," Shapiro said. "Also important, these compounds are effective in breast cancer cells in which tamoxifen acts like estrogen."

Thus, these compounds might prevent tamoxifen-resistant breast cancer from becoming more aggressive. However, Shapiro cautioned that their research is in the early stage. A future step will be testing the new estrogen receptor inhibitors in animal models of breast cancer.


'/>"/>

Contact: Aaron Lohr
alohr@endo-society.org
240-482-1380
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Cancer was one of the best things to happen to me ... but I worry about the future
2. Cancer was one of the best things to happen to me... but I worry about the future
3. Next 10 years crucial to ensure provision of clean water for future generations
4. Future of Behavioral Health Care for New Mexicos Youth Subject of Expert Panel Sponsored by ValueOptions(R)
5. Survivors of childhood Hodgkins lymphoma at higher risk of future health problems
6. Hodgkin Lymphoma Kids Face Greater Risk of Future Problems
7. New study shows sedentary high school girls are at significant risk for future osteoporosis
8. Invest in Your Future With a Spa Visit Today
9. NIDCR strategies for future scientific success
10. Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care
11. AMICAS Focuses on the Future of Radiology IT at SIIM 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , ... Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health Records: A ... Results of the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, ... recognized for adherence to the highest standards of trauma, maternity, cancer and chronic ... center's president and CEO, Dr. Daniel Messina. , Among the recognitions, the American ...
(Date:12/8/2016)... ... ... Vida Health, the digital health platform that pairs individuals with ... . Other investors include Nokia Growth Partners (NGP) and returning investor Aspect Ventures. Vida ... are managing chronic conditions or simply want to improve their health. Canvas ...
(Date:12/8/2016)... ... ... Coppin Insurance Agency, an insurance and financial planning firm based in Lee ... is embarking on a charity drive with the goal of providing support and donations ... Bank of Southwest Florida works to provide fresh and nutritious food free of charge ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Global ... report on the global interventional radiology market analyzes ... The report comprises an elaborate executive summary, including ... various segments and sub-segments. The research is ... research formed the bulk of our research efforts ...
(Date:12/8/2016)... , Dec. 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) ... a 2016 Top Workplaces National Standard. To ... ... Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ... on an employee survey administered by WorkplaceDynamics, LLC, a research firm ...
(Date:12/8/2016)... and Markets has announced the addition of the "Endodontic Supplies - Global ... , ... markets for Endodontic Supplies in US$ Thousand. The report provides separate comprehensive analytics ... Europe , Asia-Pacific , Latin ... are provided for the period 2015 through 2022. Also, a six-year historic analysis ...
Breaking Medicine Technology: